Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy is a research paper published in Journal of Clinical Investigation (2020). On theSindex it has a DataRank of 0. It has been cited 201 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Center
Grant: CA217648,CA123088,CA099985,CA193136,
National Cancer Center
Grant: CA152470,CA46592
NCI NIH HHS
Grant: P50 CA186786
NCI NIH HHS
Grant: R01 CA152470
NCI NIH HHS
Grant: R35 CA232097
NCI NIH HHS
Grant: R01 CA099985
NCI NIH HHS
Grant: R01 CA123088
NCI NIH HHS
Grant: R01 CA190176
NCI NIH HHS
Grant: R01 CA193136
NCI NIH HHS
Grant: R01 CA214911
NIAID NIH HHS
Grant: T32 AI007413
NCI NIH HHS
Grant: R01 CA211016
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: P30 CA010815
NCI NIH HHS
Grant: P30 CA046592
NCI NIH HHS
Grant: R01 CA217510
National Institutes of Health
Grant: 5R01CA123088-05
Novel immunosupressive macrophages in human ovarian tumor
National Institutes of Health
Grant: 5R01CA193136-02
MDSCs in Ovarian Cancer
National Institutes of Health
Grant: 5R01CA152470-02
Memory T Cells in the Tumor Microenvironment
National Institutes of Health
Grant: 5R01CA099985-02
Human Tregs in Ovarian Cancer
National Institutes of Health
Grant: 5T32AI007413-27
Research Training in Experimental Immunology
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 2 of Comprehensive integrative profiling of upper tract urothelial carcinomas
Additional file 2 of Comprehensive integrative profiling of upper tract urothelial carcinomas
Additional file 3 of Comprehensive integrative profiling of upper tract urothelial carcinomas
Additional file 3 of Comprehensive integrative profiling of upper tract urothelial carcinomas
Additional file 1 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 1 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 2 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 2 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 2 of Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis
Additional file 2 of Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis
Additional file 3 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 3 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 4 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 4 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 5 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 5 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 6 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 6 of ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner
Additional file 1 of Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis
Additional file 1 of Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis